Potential value of triple antiplatelet therapy for secondary stroke prevention.
D000249:Adenosine Monophosphate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004176:Dipyridamole / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012306:Risk; D020521:Stroke / Q000188:drug therapy* / Q000517:prevention & control*; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D000249:Adenosine Monophosphate; D004176:Dipyridamole; C117446:cangrelor; D001241:Aspirin